SOHO 2023 | Nivolumab + ibrutinib for patients with Richter’s transformation
Nitin Jain
• 7 Sep 2023
Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares insights into a Phase II trial investigating the combination of nivolumab and ibrutinib for patients with Richter’s transformation of chronic lymphocytic leukemia (CLL; NCT02420912). Durable remission was possible in some patients, particularly those who were not previously exposed to ibrutinib. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
